- Home
- EDBL vs SLRX Comparison
EDBL vs SLRX Comparison
Compare EDBL & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDBL | SLRX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDBL | SLRX |
|---|---|---|
| Price | $0.78 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 190.2K | ★ 348.2K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,553,000.00 | N/A |
| Revenue This Year | $29.56 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.51 |
| 52 Week High | $10.60 | $108.00 |
Technical Indicators
Market Signals| Indicator | EDBL | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 47.16 |
| Support Level | $0.48 | $0.51 |
| Resistance Level | $1.04 | $0.68 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 29.93 | 82.81 |
Price Performance
Historical ComparisonAbout EDBL Edible Garden AG Incorporated
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.